Toronto, ON – May 17, 2024 – Copoly, a pioneering leader in cancer diagnostics and biomedical research, is thrilled to announce its selection for the prestigious ALPHA program at Collision 2024, North America’s fastest-growing tech conference, held in Toronto from June 17 to June 20, 2024.
The ALPHA program, known for spotlighting the most innovative and promising startups from around the world, will provide Copoly with a unique platform to showcase its cutting-edge technologies, OncoSage and BioSage. OncoSage, our flagship product, is a blood-based early cancer detection platform, while BioSage is a generative AI tool designed for analyzing scientific literature and biomedical data.
Excitement for Collaboration and Growth
Participation in the ALPHA program at Collision 2024 marks a significant milestone for Copoly. We are eager to engage with potential investors and strategic partners to accelerate our path to commercialization and enhance our research and development efforts.
“Being selected for the ALPHA program is an incredible opportunity for Copoly,” said Dr. Peng Zhang, CEO of Copoly. “Collision 2024 offers a global stage to connect with investors and partners who share our vision of transforming cancer detection and biomedical research. We are excited to demonstrate the potential of OncoSage and explore collaborations that will drive our mission forward.”
A Vision for the Future
At Collision 2024, Copoly aims to highlight the impact of its innovative solutions on early cancer detection. OncoSage’s ability to detect cancer at its earliest stages can significantly improve patient outcomes.
“Early cancer detection is critical to improving patient care and outcomes,” added Zhang. “Through OncoSage, we are committed to making a profound difference in these areas. The ALPHA program at Collision 2024 is the perfect venue to showcase our work and form meaningful partnerships that will help us achieve our goals.”
Join Us at Collision 2024
Copoly invites all attendees of Collision 2024 to visit our booth (#A337) June 18th and learn more about our groundbreaking technologies. Our team will be available to discuss potential investment opportunities, strategic partnerships, and the future of cancer diagnostics.
For more information or to schedule a meeting with Copoly during Collision 2024, please contact Dr. Peng Zhang.
About Copoly
Copoly is dedicated to advancing cancer diagnostics and biomedical research through innovative technologies. Our flagship product, OncoSage, is a blood-based early cancer detection platform, while BioSage is a generative AI tool for scientific literature and biomedical data analysis. We strive to improve patient outcomes and accelerate scientific discoveries through cutting-edge solutions.
For media inquiries, please contact: Peng Zhang
CEO, Copoly.ai Inc
This announcement reflects Copoly’s commitment to innovation and its readiness to engage with the tech and investment communities at one of the industry’s most significant events.
